O-GlcNAcylation and Its Roles in Neurodegenerative Diseases
As a non-classical post-translational modification, O-linked β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) [...]
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential [...]
O-GlcNAcylation Regulates Dopamine Neuron Function, Survival and Degeneration in Parkinson Disease
The dopamine system in the midbrain is essential for volitional [...]
Alectos Supports NSERC Funding for Prof. A.J. Bennet at SFU
Feb 11, 2016 – Alectos today announced its support for [...]
O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson’s disease
Several aggregation-prone proteins associated with neurodegenerative diseases can be modified [...]
Fluorescence-quenched substrates for live cell imaging of human glucocerebrosidase activity
Deficiency of the lysosomal glycoside hydrolase glucocerebrosidase (GCase) leads to [...]
Alectos Supports NSERC Funding for Prof. M.J. Boulanger at UVic
Oct 6, 2014 – Alectos today announced its support for [...]
O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer’s disease and beyond
Alzheimer disease (AD) is a growing problem for aging populations [...]
O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregation
Sweet relief: the Parkinson's disease-associated protein α-synuclein is post-translationally modified [...]